Loading...
•
Dec 31, 2023
Enanta Pharmaceuticals Q1 2024 Earnings Report
Reported financial results for the fiscal first quarter ended December 31, 2023.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $18.0 million for the three months ended December 31, 2023, consisting of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®. The net loss for the quarter was $33.4 million, or $1.58 per diluted common share. Cash, cash equivalents and short-term marketable securities totaled $337.2 million at the end of the quarter.
Preparing for multiple catalysts across the pipeline in 2024, starting with RSV.
Anticipates reporting topline data from the RSVPEDs Phase 2 study of zelicapavir and the Phase 2a challenge study of EDP-323 in Q3 2024.
Expanded into immunology with a new discovery program of oral KIT inhibitors for first indication in chronic spontaneous urticaria, with development candidate selection targeted for 2024.
Cash and marketable securities totaled $337.2 million at December 31, 2023.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs through fiscal year 2027.